(Q35203994)

7 August 2017

1 reference

title

Surrogate endpoints in Parkinson's disease research (English)

1 reference

7 August 2017

1 reference

Kevin M Biglan

1

1 reference

7 August 2017

Robert G Holloway

series ordinal

2

1 reference

7 August 2017

publication date

1 July 2003

1 reference

Current Neurology and Neuroscience Reports

7 August 2017

published in

1 reference

7 August 2017

volume

3

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

314-320

1 reference

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

An approach to the validation of markers for use in AIDS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

Clinical trial end points: on the road to nowhere?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-003-0008-Y

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

21 January 2018

1 reference

12 December 2020

Intermediate markers as surrogate endpoints in cancer research

1 reference

12 December 2020

Factor structure, normative data and retest-reliability of a test of fine motor functions in patients with idiopathic Parkinson's disease

1 reference

12 December 2020

Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography

1 reference

12 December 2020

Surrogate endpoints in clinical trials: cardiovascular diseases.

1 reference

12 December 2020

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

1 reference

12 December 2020

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 December 2020

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

12 December 2020

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group

1 reference

12 December 2020

Surrogate endpoints in clinical trials: ophthalmologic disorders

1 reference

12 December 2020

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

12 December 2020

Striatal dopamine distribution in parkinsonian patients during life

1 reference

12 December 2020

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

12 December 2020

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

1 reference

12 December 2020

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

1 reference

12 December 2020

Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction.

1 reference

12 December 2020

Multiple sclerosis: use of MRI in evaluating new therapies

1 reference

12 December 2020

D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo.

1 reference

12 December 2020

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease

1 reference

12 December 2020

Perspective: validating surrogate markers--are we being naive?

1 reference

12 December 2020

Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study

1 reference

12 December 2020

Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

12 December 2020

Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor types

1 reference

12 December 2020

CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine

1 reference

12 December 2020

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

12 December 2020

Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease

1 reference

12 December 2020

Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease

1 reference

12 December 2020

Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.

1 reference

12 December 2020

Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET.

1 reference

12 December 2020

What are surrogate outcome measures and why do they fail in clinical research?

1 reference

12 December 2020

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

1 reference

12 December 2020

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

12 December 2020

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

12 December 2020

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.

1 reference

12 December 2020

10.1007/S11910-003-0008-Y

Identifiers

DOI

1 reference

7 August 2017

1 reference